|
Sep 8
|
Ozempic, Wegovy could help type 1 diabetics: Study
|
|
Sep 8
|
Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?
|
|
Sep 8
|
1 Stock Split Stock to Buy Hand Over Fist Right Now
|
|
Sep 8
|
Lars Fruergaard Jørgensen, the Novo Nordisk boss who dethroned Europe’s biggest company
|
|
Sep 8
|
25 Most Health-Conscious Cities in the US
|
|
Sep 7
|
Why Novo Nordisk Stock Topped the Market on Thursday
|
|
Sep 7
|
Unveiling Novo Nordisk A/S (NVO)'s Value: Is It Really Priced Right? A Comprehensive Guide
|
|
Sep 7
|
Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.
|
|
Sep 7
|
Is Novo Nordisk Stock a Buy Now?
|
|
Sep 7
|
1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year
|
|
Sep 7
|
Novo Nordisk Is Already Working on Ozempic 2.0. Here's How to Profit
|
|
Sep 6
|
CORRECTED-Schott Pharma to provide $1 billion-worth of cartridges for injectable weight-loss drugs - CEO
|
|
Sep 6
|
How Novo Nordisk became Europe's most valuable company
|
|
Sep 5
|
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
|
|
Sep 5
|
Novo Nordisk Becomes Europe's Most Valuable Company as Wegovy Launches in UK
|
|
Sep 5
|
REFILE-Pent-up private Wegovy demand prompts UK availability concerns
|
|
Jul 11
|
Why Novo Nordisk Stock Sank on Tuesday
|
|
Jul 11
|
The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin
|
|
Jul 11
|
UPDATE 3-EU extends Ozempic review to include more weight-loss, diabetes drugs
|
|
Jul 11
|
Novo Nordisk says Wegovy launch in Germany won't hit U.S. supplies
|